Oppenheimer & CO Inc Oramed Pharmaceuticals Inc. Transaction History

Oppenheimer & CO Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	BUY	$3.72 - $9.0 $9,486 - $22,950	2,550 Added 5.37%	50,000 $229,000
Q1 2022 May 12, 2022	BUY	$8.19 - $13.89 $61,015 - $103,480	7,450 Added 18.63%	47,450 $410,000
Q4 2021 Feb 02, 2022	BUY	$12.98 - $29.75 $67,496 - $154,700	5,200 Added 14.94%	40,000 $571,000
Q3 2021 Nov 12, 2021	BUY	$12.13 - $23.82 $100,982 - $198,301	8,325 Added 31.44%	34,800 $765,000
Q2 2021 Aug 03, 2021	SELL	$8.34 - $14.59 $11,050 - $19,331	-1,325 Reduced 4.77%	26,475 $354,000
Q1 2021 May 10, 2021	BUY	$4.22 - $11.33 $66,676 - $179,014	15,800 Added 131.67%	27,800 $282,000
Q4 2020 Feb 11, 2021	BUY	$2.48 - $4.64 $29,760 - $55,679	12,000 New	12,000 $51,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $90.9M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.